Program
NTX-2001
A development code.
Its studies are mostly in Alcoholism, led by Newleos Therapeutics.
Furthest: phase 1, since Apr 3, 20261 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newleos Therapeutics | 11 open or running | phase 1since Apr 3, 2026 | Apr 3, 2026 | Mar 2027phase 1 · NCT07520292 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2026First study: phase 1 study in AlcoholismFirst studyNCT07520292 · 50 planned · United States
Ahead
- Mar 2027Primary completion: phase 1 study in AlcoholismNCT07520292
TargetBeta
TAAR1 →read by rule
“The Effects of NTX-2001, a Novel TAAR1 Partial Agonist, on Alcohol Consumption in Adults With Alcohol Use Disorder: A Phase 1b, Randomized, Placebo-Controlled, Proof-of-Concept Study”study text, by rule · the study
Other programs on TAAR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ulotarontrule | Otsuka | phase 3 | 30 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07520292Alcoholism · United States | 1 | Recruiting | Mar 2027 | 50 |
How it is read
Names in the registry
- “NTX-2001”, 1 entry
Codes read as this program: NTX2001.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.